Previsão
O preço-alvo médio dos analistas é € 64,98 (+48,09%). A mediana é € 64,71 (+47,47%).
| Comprar |
13 |
| Manter |
2 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Scholar Rock clarifies FDA requirements for ISEMBYLD, shares fall sharply
Scholar Rock confirmed that the FDA requires post‑marketing conditions for ISEMBYLD, including a study on safety in pregnancy and 15‑day adverse‑event reporting for bone fractures. Management had previously (and incorrectly) stated that no such conditions existed. The stock then fell 6.4% to $51.85 and declined 9.7% on the week. Scholar Rock said it will carry out the requested studies and reporting in line with FDA requirements; analysts subsequently adjusted ratings and price targets. » Mais em de.investing.com
FDA grants approval for ISEMBYLD; Scholar Rock stock rises
The FDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-specific treatment for spinal muscular atrophy in adults and children aged two and older who are already receiving an SMN2-directed therapy. The news pushed Scholar Rock’s stock up about 9% pre-market to $60.45 and converts the company into a commercial biopharma company. Several analysts sharply raised price targets and reiterated buy ratings; apitegromab is projected to generate billions in sales by 2035. Scholar Rock reports roughly $492 million in cash and has independent fill-and-finish and manufacturing capabilities for the product launch. » Mais em de.investing.com
Scholar Rock receives FDA approval for Isembyld to treat SMA
The FDA has approved Isembyld (Apitegromab‑mstn) for the treatment of spinal muscular atrophy in patients aged two and older. The approval is based on the phase‑3 SAPPHIRE study, in which patients receiving Isembyld in addition to standard therapy showed a significant improvement on the Hammersmith scale after one year; 34.2% achieved an increase of at least three points versus 13.5% with placebo. The US commercial launch has begun, the stock climbed more than 14% to an all‑time high, and Scholar Rock is shifting from a clinical biotech company to a commercial drugmaker. » Mais em deraktionaer.de
Scholar Rock prepares for FDA decision on apitegromab
Weeks before the PDUFA date on September 30, 2026, Scholar Rock highlights late Phase III data on apitegromab as well as secured commercial production and go‑to‑market infrastructure. After an earlier Complete Response Letter over manufacturing issues, the company moved commercial fill‑finish production to an alternative site and says it has already produced commercial vials there. Management emphasizes statistically significant Phase III results, high treatment adherence, and prepared sales, nursing and patient‑support structures for the US, with plans for Europe and Japan. » Mais em de.investing.com
Scholar Rock nears approval for apitegromab
At the Cantor Fitzgerald Global Healthcare Conference, Scholar Rock said the FDA has identified compliance with manufacturing requirements as the only remaining approval hurdle and that the company has since established a contractually committed alternative fill-and-finish facility. The crucial PDUFA date is September 30, 2026; management is holding intensive talks with the FDA about labeling and safety data. Scholar Rock has roughly $500 million in cash, sees worldwide market potential in the billions, and expects initial but manageable reimbursement and market-access hurdles during the first three to five quarters after launch. » Mais em de.investing.com
Dados financeiros
No último trimestre, SCHOLAR ROCK HLDG DL-,001 registou receitas de € 503,22 mil e um ganho líquido de -€ 94,68 mi
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 503,22 mil | - |
| Ganho bruto | 496,16 mil | 101,15% |
| Ganho líquido | -94,68 mi | 8,69% |
| EBITDA | -90,36 mi | 5,55% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 5,35 bi |
Número de ações | 122 mi |
Máximo/mínimo de 52 semanas | € 56,28 - € 35,26 |
| Dividendos | Não |
Beta | 0,62 |
PER (PE Ratio) | -14,95 |
PEG (PEG Ratio) | 28,66 |
P/VC (PB Ratio) | 37,77 |
P/V (PS Ratio) | 10.301,85 |
Perfil da empresa
A Scholar Rock Holding Corporation, uma empresa biofarmacêutica, dedica-se à descoberta e ao desenvolvimento de medicamentos para o tratamento de doenças graves em que a sinalização por fatores de crescimento proteicos desempenha um papel fundamental. A empresa desenvolve a Apitegromab, um inibidor da ativação da miostatina latente que concluiu os ensaios clínicos de Fase 3 para o tratamento da atrofia muscular espinhal; e o SRK-181, que se encontra em ensaios clínicos de Fase 1 para o tratamento de cancros resistentes às terapias com inibidores de checkpoint, como as terapias com anticorpos anti-PD-1 ou anti-PD-L1. A empresa desenvolve também um portefólio de novos candidatos a medicamentos com potencial para transformar a vida de doentes que sofrem de uma série de doenças graves, incluindo distúrbios neuromusculares, cancro e fibrose. A empresa tem um acordo de colaboração com a Gilead Sciences, Inc. para descobrir e desenvolver inibidores específicos da ativação do fator de crescimento transformador beta para o tratamento de doenças fibróticas. A Scholar Rock Holding Corporation foi fundada em 2012 e tem sede em Cambridge, Massachusetts.
| Nome | SCHOLAR ROCK HLDG DL-,001 |
| CEO | David L. Hallal |
| Sede | Cambridge,
ma EUA |
| Site | |
| Setor | Bens de consumo básico |
| Indústria | Produtos alimentares |
| Entrada em bolsa | 25/05/2018 |
| Colaboradores | 289 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | SRRK |
Frankfurt | 2QK.F |
Düsseldorf | 2QK.DU |
München | 2QK.MU |